Encompass Health (EHC) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
5 May, 2026Executive summary
Net operating revenue for Q1 2026 rose 9.0% year-over-year to $1,586.6 million, with adjusted EBITDA up 11.2% to $348.8 million and adjusted EPS up 16.8% to $1.60.
Net income attributable to shareholders increased 28.4% to $194.5 million, with diluted EPS from continuing operations up 19.6% to $1.77.
Opened a new 49-bed hospital in South Carolina and added 44 beds to existing hospitals in Q1 2026.
Paid a quarterly dividend of $0.19 per share and repurchased approximately 708,000 shares for $71.6 million.
Patient outcomes and quality metrics improved, with discharge TME rates at 84.5% and RN turnover at its lowest since 2012.
Financial highlights
Net patient revenue per discharge rose 3.7% year-over-year to $22,633, aided by patient mix and favorable Medicare SSI adjustment.
Adjusted free cash flow for Q1 was $193.8 million, down from $222.4 million in Q1 2025.
Salaries and benefits as a percentage of revenue decreased to 51.6% from 52.4% year-over-year.
Bad debt expense rose 20 basis points to 2.2% due to legacy audit claim write-offs.
Adjusted EBITDA margin improved to approximately 22%.
Outlook and guidance
2026 net operating revenue expected at $6,375–$6,470 million, adjusted EBITDA at $1,350–$1,380 million, and adjusted EPS at $5.89–$6.11.
Plans to open 7–8 new hospitals and add 100–175 beds to existing facilities in 2026.
Pipeline includes 11 hospitals with 520 beds scheduled to open beyond 2026.
Medicare pricing expected to increase ~3.0% for Q1–Q3 and 2.4% for Q4 2026; managed care pricing up 2.0–3.0%.
Adjusted free cash flow for 2026 expected between $760–$875 million.
Latest events from Encompass Health
- All board, auditor, and compensation proposals passed; no shareholder questions submitted.EHC
AGM 20267 May 2026 - Virtual annual meeting to elect directors, ratify auditor, and approve performance-based executive pay.EHC
Proxy filing7 Apr 2026 - Expansion, innovation, and disciplined capital use drive positive outlook and operational momentum.EHC
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Double-digit growth in revenue, EBITDA, and EPS in 2025, with strong 2026 outlook.EHC
Q4 20256 Feb 2026 - Double-digit revenue and earnings growth in Q1 led to higher full-year guidance.EHC
Q1 20253 Feb 2026 - Q2 2024 revenue rose 9.6% and net income 24.8%, prompting higher full-year guidance.EHC
Q2 20242 Feb 2026 - Q3 2024 saw 11.9% revenue growth, higher earnings, and a raised full-year outlook.EHC
Q3 202418 Jan 2026 - Q4 2024 saw strong growth in revenue, earnings, and cash flow, with a positive 2025 outlook.EHC
Q4 20248 Jan 2026 - All voting items passed with strong support and no stockholder questions were raised.EHC
AGM 202524 Dec 2025